Dissemond, Joachim http://orcid.org/0000-0003-3893-328X
Marzano, Angelo V.
Hampton, Philip J.
Ortega-Loayza, Alex G.
Funding for this research was provided by:
Universitätsklinikum Essen
Article History
Accepted: 1 August 2023
First Online: 23 August 2023
Declarations
:
: Open Access funding enabled and organized by Projekt DEAL. None.
: Dissemond received educational and research funding and/or contributed to advisory work for Infectopharm, InflaRx, Jansen Cilag and Novartis. Marzano received educational and research funding and/or contributed to advisory work for Abbvie, Boehringer-Ingelheim, Novartis, Pfizer, Sanofi and UCB. Hampton received educational and research funding and/or contributed to advisory work for Abbvie, Almiral, UCB, Jansen and Novartis. Ortega Loayza received educational and research funding and/or contributed to advisory work for Genentech, Guidepoint, Bristol Meyer Squibb, Boehringer Ingelheim, Janssen, Lilly, Janssen and Pfizer.
: Not applicable
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: JD: Planning, writing several sections, revision of the whole manuscript. AVN: Writing one section, revision of the whole manuscript. PJH: Writing one section, revision of the whole manuscript. AGOL: Planning, writing several sections, revision of the whole manuscript. All authors read and approved the final manuscript.